Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer

Preface.
 
Contributors.
 
1. Antibody Engineering: Optimizing the Delivery Vehicle (Diane E. Milenic).
 
1.1 Introduction.
 
1.2 Intact Murine Monoclonal Antibodies.
 
1.3 Recombinant Immunoglobulin Molecules.
 
1.4 Nanobodies.
 
1.5 Domain-Deleted Monoclonal Antibodies.
 
1.6 Hypervariable Domain Region Peptides.
 
1.7 Fv Fragments.
 
1.8 Minibodies.
 
1.9 Selective High Affinity Ligands.
 
1.10 Affibodies.
 
1.11 Other Strategies.
 
1.12 Concluding Remarks.
 
References.
 
2. The Radiochemistry of Monoclonal Antibodies and Peptides (Raymond M. Reilly).
 
2.1 Introduction.
 
2.2 Tumor and Normal Tissue Uptake of Monoclonal Antibodies and Peptides.
 
2.3 Selection of a Radionuclide for Tumor Imaging.
 
2.4 Selection of a Radionuclide for Targeted Radiotherapy.
 
2.5 Labeling Antibodies and Peptides with Radiohalogens.
 
2.6 Labeling Antibodies and Peptides with Radiometals.
 
2.7 Characterization of Radiolabeled mAbs and Peptides.
 
2.8 Summary.
 
Acknowledgments.
 
References.
 
3. The Design of Radiolabeled Peptides for Targeting Malignancies (Leonard G. Luyt).
 
3.1 Introduction.
 
3.2 Peptide Targets.
 
3.3 Peptides as Cancer Targeting Agents.
 
3.4 Multimodality Agents.
 
3.5 Future Outlook.
 
References.
 
4. Peptide Receptor Radionuclide Therapy in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors (Martijn van Essen, Dik J. Kwekkeboom, Wouter W. de Herder, Lisa Bodei, Boen L. R. Kam, Marion de Jong, Roelf Valkema, and Eric P. Krenning).
 
4.1 Introduction.
 
4.2 Radiotherapy with 111In-Octreotide.
 
4.3 Radiotherapy with 90Y-DOTATOC.
 
4.4 Targeted Radiotherapy Studies with 177Lu-Octreotate.
 
4.5 PRRT with Other Somatostatin Analogues.
 
4.6 Comparison of Different

RAYMOND M. REILLY is a Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto. He has more than twenty years of experience in the field of radiolabeled antibody and peptide targeting of cancer. Dr. Reilly has written over 180 publications in the field, including more than 100 scientific papers on radiopharmaceuticals for cancer imaging and targeted radiotherapy.

"The book is well written and the topics of individual chapters are wisely chosen in order to cover the most important aspects of targeted radionuclide therapy. This book gives rich insights into theoretical and practical aspects of targeted radionuclide therapy, particularly considering its position as a rapidly emerging, exciting, new therapy modality for cancer. It speaks in favor of this book that valuable information is available for people entering the field, as well as for experienced researchers who need profound information." (ChemMedChem, November 2010)

"The book is well written and the topics of individual chapters are wisely chosen in order to cover the most important aspects of targeted radionuclide therapy. This book gives rich insights into theoretical and practical aspects of targeted radionuclide therapy, particularly considering its position as a rapidly emerging, exciting, new therapy modality for cancer. It speaks in favor of this book that valuable information is available for people entering the field, as well as for experienced researchers who need profound information." ( ChemMedChem , November 2010)